Login / Signup

NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.

Yu-Chuan LuChen-Hsun HoJian-Hua HongMing-Chieh KuoYi-An LiaoFu-Shan JawJason Chia-Hsien ChengChao-Yuan HuangKo-Ping ChangChung-Hsin ChenJung-An LinAn HsiaoHsiu-Ni Kung
Published in: Molecular oncology (2023)
Extracellular vesicles (EVs) are an important regulatory factor for natural killer cell activity (NKA) in the tumor microenvironment. The relationship between circulating EVs in the peripheral blood and natural killer (NK) cells in prostate cancer is unclear. This study aims to investigate the key regulators in the interaction between circulating EVs and NK cells in prostate cancer patients before and after tumor removal. NK-cell characteristics were prospectively assessed in 79 patients treated with robot-assisted laparoscopic radical prostatectomy (RARP) preoperatively and postoperatively. Compared with healthy donors, the existence of prostate tumors increased the number of circulating EVs and altered ligand expression of EVs. Circulating EVs extracted from cancer patients significantly decreased NKA of NK cells compared to those extracted from healthy donors. Upon treatment with an inhibiting antibody or small interfering RNA (siRNA), natural killer cell protein group 2A (NKG2A) was identified as the main NKA regulator in cancer patients for accepting the signal from circulating EVs. After surgery, NKA was increased and NKG2A expression on NK cells was significantly reduced. The expression of ligands for NKG2D on EVs and the level of circulation EVs both significantly increased. With the decrease in NKG2A levels on NK cells and the increase in total NKG2D ligands on circulating EVs, which was increased postoperatively, both NKG2A on NK cells and NKG2D ligands on circulating exosomes are main regulators of NKA restoration after prostatectomy.
Keyphrases
  • nk cells
  • prostate cancer
  • radical prostatectomy
  • robot assisted
  • poor prognosis
  • peripheral blood
  • minimally invasive
  • stem cells
  • binding protein
  • mesenchymal stem cells
  • signaling pathway
  • drug delivery
  • cancer therapy